ST. LOUIS, May 24 /PRNewswire-FirstCall/ -- Centene Corporation (NYSE: CNC) issued a final reminder today regarding its previouslyannounced eighth annual Investor Day. The event will be held on Wednesday, June 2, 2010, at the New York Helmsley Hotel on East 42nd Street in New York City. The meeting, which also will
Institutional investors and analysts interested in attending the investor day event can respond to Libby Abelt in Centene's Investor Relations department either via telephone at 1-212-759-5665 or e-mail at: firstname.lastname@example.org.
Interested parties may listen to the live, audio webcast of the event by going to the Company's website at www.centene.com and accessing the Investor Relations section. A webcast replay will also be available via Centene's IR section on its website immediately following the event.
About Centene Corporation
Centene Corporation, a Fortune 500 company, is a leading multi-line healthcare enterprise that provides programs and related services to the rising number of under-insured and uninsured individuals. Many receive benefits provided under Medicaid, including the State Children's Health Insurance Program (CHIP), as well as Aged, Blind or Disabled (ABD), Foster Care and long-term care, in addition to other state-sponsored programs, and Medicare (Special Needs Plans). Centene's CeltiCare subsidiary offers states unique, "exchange-based" and other cost-effective coverage solutions for low-income populations. The Company operates local health plans and offers a range of health insurance solutions. It also contracts with other healthcare and commercial organizations to provide specialty services including behavioral health, life and health management, managed vision, telehealth services, and pharmacy benefits management. More information regarding Centene is available at www.centene.com.
SOURCE Centene Corporation
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All